[A22-122] Tezepelumab (severe asthma) – Benefit assessment according to § 35a SGB V
Last updated 15.02.2023
Project no.:
A22-122
Commission:
Commission awarded on 15.11.2022 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Patients with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment
- Adolescents aged 12 to 17 years: added benefit not proven
- Adults: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-02-15.
| Project no. | Title | Status |
|---|---|---|
| A25-145 | Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V | Commission completed |